Inrig Julainsider trades
In SEC Form 4 filings, Inrig Jula is listed as EVP, Head of R&D & CMO of Travere Therapeutics, Inc. (TVTX). In the last 90 days, Inrig Jula sold $2.79M of Travere Therapeutics, Inc. (TVTX) on the open market and bought none. All 4 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| TVTXTravere Therapeutics, Inc. | EVP, Head of R&D & CMO | 6 | Sep 17 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-17
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| TVTXTravere Therapeutics, Inc. | Sep 15 | Sep 17 | M | 32,395 | $8.93 | $289,287 | 145,165 | Yes | Form 4 |
| TVTXTravere Therapeutics, Inc. | Sep 15 | Sep 17 | S | 25,390 | $62.02 | Sale −$1,574,604 | 119,775 | Yes | Form 4 |
| TVTXTravere Therapeutics, Inc. | Sep 15 | Sep 17 | S | 17,284 | $62.62 | Sale −$1,082,397 | 102,491 | Yes | Form 4 |
| TVTXTravere Therapeutics, Inc. | Sep 15 | Sep 17 | S | 1,600 | $63.69 | Sale −$101,896 | 100,891 | Yes | Form 4 |
| TVTXTravere Therapeutics, Inc. | Sep 15 | Sep 17 | S | 400 | $65.31 | Sale −$26,124 | 100,491 | Yes | Form 4 |
| TVTXTravere Therapeutics, Inc. | Sep 15 | Sep 17 | M · derivative | 32,395 | $8.93 | $289,287 | 43,605 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.